Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.88M | $28.3M | $2.30M | — | — | — |
| Revenue growth | — | 883.1% | -91.9% | — | — | — |
| Operating income | -$55.3M | -$39.3M | -$23.7M | -$35.7M | -$45.0M | -$37.7M |
| Operating margin | -1919.2% | -138.8% | -1031.4% | — | — | — |
| Net income | -$80.1M | -$54.6M | -$28.2M | -$35.2M | -$51.9M | -$39.6M |
| Net margin | -2781.5% | -192.8% | -1225.9% | — | — | — |
| EPS (diluted) | -$5.43 | -$1.93 | -$89.27 | -$6.96 | -$4.25 | -$2.58 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$22.9M | -$52.6M | -$22.2M | -$32.7M | -$37.1M | -$37.0M |
| Capital expenditures | $41.0K | $382K | $654K | $66.0K | $87.0K | $16.0K |
| Free cash flow | -$22.9M | -$53.0M | -$22.8M | -$32.8M | -$37.2M | -$37.0M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $34.6M | $88.8M | $6.16M | $12.9M | $17.6M | $18.6M |
| Total assets | $47.3M | $96.5M | $22.7M | $27.1M | $28.2M | $25.9M |
| Total liabilities | $138M | $15.0M | $13.7M | $15.8M | $39.5M | $24.2M |
| Long-term debt | $635K | $0.00 | — | — | $20.0M | $9.41M |
| Shareholders' equity | -$90.4M | -$74.5M | -$102M | $11.4M | -$11.3M | $1.64M |
| Retained earnings | -$161M | -$215M | -$107M | -$142M | -$194M | -$234M |
| Shares (wtd avg diluted) | 14.8M | 28.2M | 316K | 9.70M | 12.2M | 15.3M |
Every figure is extracted from Elicio Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.